GRYPHON CAPITAL INCOME TRUST (GCI)

---

AI Coverage Rating: Active

ASX AI Signals has generated 5 signal for GCI during the last 90 days, indicating active trading activity and ongoing AI monitoring

Latest GCI Signals
22/06/2026	BUY
21/06/2026	BUY
20/06/2026	BUY
GCI Share Price
Current Price	$2.070
52 Week High	$2.080
52 Week Low:	$1.932
Trading at (% of 52 Week High)	99.52%

Business Overview

Gryphon Capital Income Trust (ASX: GCI) is an Australian investment trust that focuses on providing regular income returns through a diversified portfolio. The company primarily invests in a mix of Australian and global assets, including equities, fixed income, and alternative investments. Its goal is to deliver consistent income for its investors.

ASX Sector Overview

Sector:   Not Applic

The "Not Applic" sector on the ASX typically includes companies that do not fit into the standard sector classifications. These entities might operate in niche markets, hold diverse business activities, or be involved in areas that are not clearly defined within traditional sectors. This grouping serves as a category for unique or emerging businesses that are still establishing their core operations. As a result, the sector can be quite varied in terms of industry focus and business models.

Latest AI Recommendation

The BUY signal for GRYPHON CAPITAL INCOME TRUST (GCI) is supported by its current valuation and income-focused strategy, but moderate market volatility and sector-specific risks temper the confidence level.

Latest  GRYPHON CAPITAL INCOME TRUST(GCI)   News

05 Mar 2021, 11:00 PM

RedHill to Present at Upcoming Conferences in March

TEL AVIV, Israel and RALEIGH, NC, March 5, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: RedHill Biopharma Sachs Spring Life

03 Mar 2021, 12:23 AM

RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares

TEL AVIV, Israel and RALEIGH, NC, March 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering a

23 Feb 2021, 11:33 PM

RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.

Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S. The study has enrolled over 50% of the targeted 464 patients globally; U.S. study activities expected to expand the stu